Rhumbline Advisers Has $15.38 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Rhumbline Advisers trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,325 shares of the medical research company’s stock after selling 3,009 shares during the period. Rhumbline Advisers owned approximately 0.16% of Charles River Laboratories International worth $15,382,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. raised its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $59,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $163.11 on Friday. The company has a fifty day simple moving average of $172.84 and a 200 day simple moving average of $188.09. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a PEG ratio of 4.54 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the prior year, the business posted $2.46 EPS. The business’s revenue was down 1.1% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday. Barclays lowered their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $195.71.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick purchased 1,514 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).